Tenet Healthcare Jumps 46% YTD & Trades Cheap: Should You Buy Now?

Tenet Healthcare (THC) has significantly outperformed, surging 46% year-to-date, driven by an upgraded 2025 outlook projecting higher adjusted admissions, EBITDA between $4.4 billion and $4.54 billion, and expanded margins of 21-21.4%. The company's strategic focus on expanding its ambulatory network, investing in AI, and divesting non-core assets has strengthened its financial position, evidenced by a lower net debt-to-capital ratio and robust free cash flow targets. Despite its strong performance, THC trades at a valuation discount to the industry, with analysts forecasting continued EPS growth and maintaining a 'Strong Buy' rating, positioning it as a compelling opportunity in the healthcare sector.

Analysis

Tenet Healthcare (THC) has demonstrated significant market outperformance, with its stock appreciating 46% year-to-date, substantially outpacing peers HCA Healthcare (+34.6%) and Universal Health Services (+1.2%). This momentum is underpinned by robust fundamentals, highlighted by an upgraded 2025 outlook following strong second-quarter results. The company now projects adjusted EBITDA between $4.4 billion and $4.54 billion, a notable increase from the prior range, with expected margin expansion to 21-21.4%. Strategically, THC is focusing on higher-margin ambulatory services, with a network of 521 centers, targeting adjusted free cash flow of $2.175–$2.375 billion for 2025. This focus is complemented by disciplined capital management, including divesting non-core hospital assets to reduce leverage, resulting in a net debt-to-capital ratio of 56.6%, well below the 91.3% industry average. Despite its strong price performance, the stock's valuation remains attractive, trading at a forward P/E multiple of 11.58x, which is a discount to the industry average of 13.28x. Analyst sentiment is firmly positive, reflected in consistent upward earnings estimate revisions, with consensus projecting a 30.8% YoY surge in adjusted EPS for 2025.

Key Decisions for Investors

• Given the combination of strong operational momentum, upgraded guidance, and a valuation discount relative to the industry, investors may view THC as a compelling growth-at-a-reasonable-price (GARP) opportunity in the healthcare sector.
• Investors should monitor the execution of the company's ambulatory expansion and its ability to achieve the guided EBITDA margin of 21-21.4%, as these are the primary drivers for its projected free cash flow and continued re-rating.
• While the stock is trading near its 52-week high, the 7.2% implied upside to the average analyst price target of $197.65 and its consistent history of earnings beats suggest that further positive surprises or sustained execution could drive the stock higher.
• Consider the company's strong financial health, with a low debt ratio and significant cash reserves, as a key mitigating factor against potential sector-wide volatility or regulatory headwinds.